EIDD-1931, is a mutagenic antiviral drug created by Emory Institute of Drug Development. It is related to Molnupiravir that are use to treat Covid 19 in humands and FIP in cats. EIDD-1931 garnered public attention in early 2023 following a series of independent clinical studies conducted by researchers and real world treatments conducted by veterinarians worldwide. These studies and treatments demonstrated EIDD-1931's effectiveness against feline infectious peritonitis (FIP).

Feline infectious peritonitis (FIP) is a fast-progressing and devastating disease. Many cats can become critically ill within weeks if treatment is delayed, and without medical intervention, FIP has long been considered fatal. In the United States, treatment options such as GS-441524 can be extremely costly, often placing a heavy financial burden on families in addition to veterinary care. MolnuFIP™'s EIDD-1931 offers a more accessible treatment option for cats diagnosed with FIP. It targets the virus responsible for the disease and has helped many cats show visible improvement within the first one to two weeks of treatment. When used under veterinary guidance, molnupiravir has demonstrated a favorable safety profile and has been associated with strong, lasting recoveries—giving cat owners renewed hope during an incredibly difficult time. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114919/#:~:text=FIP%20is%20a%20fatal%20immune,found%20in%20cats%20%5B4%5D.

Yes. EIDD-1931 has been extensively studied in feline viral diseases, including feline infectious peritonitis (FIP) and feline calicivirus (FCV), across multiple university-led and independent research settings. Published data indicate that EIDD-1931 demonstrates significantly higher antiviral activity—approximately 4 to 10 times greater—than its prodrug molnupiravir (EIDD-2801). In these studies, cats treated for FIP showed rapid clinical improvement, often within the first week of therapy, while FCV-related disease demonstrated consistent and meaningful viral load suppression, correlating with clinical recovery. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227765/

According to the clinical study published on the National Institutes of Health (USA), 46.2% of cats exhibit clinical signs of improvement within the first week, 84.6% within two weeks, and 92% by the third week. This is a good representation of real world treatment results. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612227/

Yes, MolnuFIP™ (EIDD-1931) is conveniently provided in easy-to-use soft gel capsules. The capsules can be given orally or opened and mixed with your cat’s food, making at-home treatment simple and stress-free.

MolnuFIP™ (EIDD-1931) is suitable for many cats undergoing FIP treatment. In some situations—such as when a cat is experiencing digestive difficulties or neurological symptoms—veterinarians may advise starting with GS-441524 injections to help stabilize the condition more quickly. GS-441524 is available through trusted providers like CUREFIP.COM (global) and BASMIFIP.COM (Southeast Asia). Once your cat shows signs of improvement, many owners find it convenient to transition to EIDD-1931 for ongoing care and simpler at-home administration, always with veterinary guidance.

EIDD-1931 treatment is typically used for up to 60 days. Many cats begin with an initial 30-day course, which is often sufficient to achieve significant FIP viral load reduction and overall improvement. If symptoms have not fully resolved, treatment may be continued for an additional 30 days. If symptoms persist beyond 60 days, it is important to consult your veterinarian. In some cases, your vet may recommend adjusting the treatment approach or transitioning to GS-441524 injectable to support continued recovery.

Administer one capsule every 12 hours for every 2.5 kg of your cat's body weight. Capsules can be given on an empty stomach or with food. If your cat vomits within 30 minutes, give another dose.

Pharmaceutical drug EIDD-2801, commercially known as Molnupiravir is a prodrug commonly used to treat COVID-19 in humans. Upon ingestion by humans or animals, EIDD-2801 is converted by the body into its active form, EIDD-1931. Clinical researches conducted in the USA and China have shown that EIDD-1931 offered by Molnufip.com is 4.4 times more potent than EIDD-2801 and does not require the body to make the conversion. Additionally, EIDD-1931 exhibits 33% lower cytotoxicity in in vitro tests. Cytotoxicity often leads to undesired and sometimes hard to manage side effects. These findings suggest that EIDD-1931 is a safer and more effective option for treating FIP than Molnupiravir due to its higher potency and lower cytotoxicity.

Yes, it is the most cost effective treatment against FIP available today. A 30 days treatment course starts from $39, which is approximately 10x cheaper than alternative FIP treatments GS-441524.

On average, cats under EIDD-1931 treatment experience 97% success rate in treatment by adhering to our prescribed treatment protocol of 1 capsule every 12 hours for every 2.5kg of body weight. Consult your veterinarian before deviating from our recommended treatment protocol.

EIDD-1931 treatment is not suitable for all FIP infections. Cats exhibiting ocular or neurological symptoms, are in critical conditions, lacking appetite, or have pre-existing liver and kidney conditions should start with 2-4 weeks of GS-441524 injections, or until these conditions are resolved before using EIDD-1931. To purchase GS-441524 visit: https://www.curefip.com

Molnupiravir EIDD-1931 is not recommended for: cats with neurological or ocular FIP symptoms. cats with digestive problems. cats in critical conditions. cats with preexisting liver or kidney conditions. when treatments exceed 60 days.